Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Medtronic
Queensland Health
QuintilesIMS
Federal Trade Commission
Argus Health
Harvard Business School
McKesson
Merck

Generated: September 21, 2018

DrugPatentWatch Database Preview

Natamycin - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for natamycin and what is the scope of natamycin patent protection?

Natamycin is the generic ingredient in one branded drug marketed by Novartis Pharms Corp and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for natamycin. One supplier is listed for this compound.

Summary for natamycin
Pharmacology for natamycin
Ingredient-typePolyenes
Drug ClassPolyene Antimicrobial
Medical Subject Heading (MeSH) Categories for natamycin
Synonyms for natamycin
(1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-(((2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-t
(1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-Amino-3,6-dideoxy-?-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-penta
(1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0~5,7~]octacosa-8,14,16,18,20-pentaene-25-carboxylic ac
(5R,7R,24S)-22R-[(3S-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1R,3S,26S-trihydroxy-12R-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8E,14E,16E,18E,20E-pentaene-25R-carboxylic acid
16-(3-Amino-3,6-didesoxy-beta-D-mannopyranosyloxy)-5,6-epoxy-8,12,14-trihydroxy-26-methyl-2,10-dioxo-1-oxacyclohexacosa-3,17,19,21,23-pentaen-13-carbonsaeure
681N938
7681-93-8
8O0C852CPO
AKOS030485970
Antibiotic A 5283
Antibiotic A-5283
BDBM50370755
CAS-7681-93-8
CL 12,625
CL 12625
CL-12625
CS-1909
Delvocid
Delvolan
Delvopos
DSSTox_CID_1163
DSSTox_GSID_21163
DSSTox_RID_75985
DTXSID6021163
E 235
E235
EINECS 231-683-5
ene-25-carboxylic acid
HY-B0133
MFCD00135085
MolPort-003-939-127
Mycophyt
Myprozine
myuprozine
Natacyn
Natafucin
Natamicina
Natamicina [INN-Spanish]
Natamycin [USAN:USP:INN:BAN]
Natamycin, pharmaceutical secondary standard; traceable to USP
Natamycin, United States Pharmacopeia (USP) Reference Standard
Natamycin, VETRANAL(TM), analytical standard
Natamycin(Pimaricin)
Natamycine
Natamycine [INN-French]
Natamycinum
Natamycinum [INN-Latin]
NCGC00016686-01
NICOTINAMIDE_ADENINE_DINUCLEOTIDE
Pimafucin
Pimaracin
pimaricin
Pimaricin preparation, ~2.5%, aqueous suspension
Pimaricin, from Streptomyces chattanoogensis, >=95% (HPLC)
Pimaricine
Pimarizin
Pimarizin [German]
rioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid
RL04928
SCHEMBL18140
Stereoisomer of 22-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo(22.3.1.0(sup 5,7))octacosa-8,14,16,18,20-pentaene-25-carboxylic acid
Synogil
Tennecetin
Tox21_110561
UNII-8O0C852CPO
ZINC8220909

US Patents and Regulatory Information for natamycin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp NATACYN natamycin SUSPENSION;OPHTHALMIC 050514-001 Approved Prior to Jan 1, 1982 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Medtronic
Queensland Health
QuintilesIMS
Federal Trade Commission
Argus Health
Harvard Business School
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.